Sugammadex: clinical development and practical use.
10.4097/kjae.2013.65.6.495
- Author:
Thomas FUCHS-BUDER
1
;
Claude MEISTELMAN
;
Julien RAFT
Author Information
1. Department of Anesthesiology, Centre Hospitalier Universitaire de NANCY, Hopital de Brabois, Vandoeuvre, France. t.fuchs-buder@chu-nancy.fr
- Publication Type:Review
- Keywords:
Cyclodextrins;
Neostigmine;
Neuromuscular block;
Residual neuromuscular blockade;
Rocuronium;
Sugammadex
- MeSH:
Cholinesterase Inhibitors;
Cyclodextrins;
Neostigmine;
Neuromuscular Blockade;
Neuromuscular Depolarizing Agents;
Paralysis;
Succinylcholine
- From:Korean Journal of Anesthesiology
2013;65(6):495-500
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sugammadex is belonging to a new class of drugs: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non depolarizing muscle relaxants. The mains advantages of sugammadex when compared with conventional anticholinesterase agents are a much faster recovery time and the unique ability, for the first time, to reverse rapidly and efficiently deep levels of neuromuscular blockade. However it only works for reversal of rocuronium or vecuronium-induced neuromuscular blockade. When administered 3 min after rocuronium the use of a large dose (16 mg/kg) can even reverse rocuronium significantly faster than the spontaneous recovery after succinylcholine.
